We thus believe that a HER2-positive breast cancer cells response to lapatinib, where treatment results in a decrease in MEK/MAPK phosphorylation whilst increasing AKT phosphorylation may act as a potential biomarker of sensitivity to refametinib. The gene discussed is ERBB2; the disease is breast cancer.